Limits...
The development of anticholinergics in the management of COPD.

Scullion JE - Int J Chron Obstruct Pulmon Dis (2007)

Bottom Line: Anticholinergics have been used to treat obstructive respiratory disease for many years from historical preparations of the deadly nightshade genus, to the more recent developments ofipratropium, oxitropium, and tiotropium.The medical treatment of airways obstruction has focused on achieving maximal airway function through bronchodilators.Of the two main bronchodilators, beta2-agonists are often the first treatment choice although there is evidence of equivalence and some suggestions of the superiority of anticholinergics in chronic obstructive pulmonary disease (COPD).

View Article: PubMed Central - PubMed

Affiliation: University Hospitals of Leicester Glenfield Site, Institute for Lung Health, Leicester, UK. jane.scullion@uhl-tr.nhs.uk

ABSTRACT
Anticholinergics have been used to treat obstructive respiratory disease for many years from historical preparations of the deadly nightshade genus, to the more recent developments ofipratropium, oxitropium, and tiotropium. The medical treatment of airways obstruction has focused on achieving maximal airway function through bronchodilators. Of the two main bronchodilators, beta2-agonists are often the first treatment choice although there is evidence of equivalence and some suggestions of the superiority of anticholinergics in chronic obstructive pulmonary disease (COPD). The following review looks at the background of anticholinergics, their pharmacological properties, and the evidence for use with suggestions for their place in the treatment of COPD.

Show MeSH

Related in: MedlinePlus

The Spiriva® HandiHaler® (Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2692120&req=5

f1-copd-2-33: The Spiriva® HandiHaler® (Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA).

Mentions: Tiotropium bromide is delivered to the lungs by inhalation through a device known as the Spiriva® HandiHaler® (Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA) (Figure 1). a device developed specifically for use by patients with COPD and tested at variable inspiratory flow rates, which enables use by patients at all levels of disease severity. The device delivers individual doses by means of a capsule inserted into the device that is then activated and subsequently inhaled. It is a once daily dose, which may be beneficial in terms of adherence with treatment.


The development of anticholinergics in the management of COPD.

Scullion JE - Int J Chron Obstruct Pulmon Dis (2007)

The Spiriva® HandiHaler® (Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2692120&req=5

f1-copd-2-33: The Spiriva® HandiHaler® (Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA).
Mentions: Tiotropium bromide is delivered to the lungs by inhalation through a device known as the Spiriva® HandiHaler® (Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA) (Figure 1). a device developed specifically for use by patients with COPD and tested at variable inspiratory flow rates, which enables use by patients at all levels of disease severity. The device delivers individual doses by means of a capsule inserted into the device that is then activated and subsequently inhaled. It is a once daily dose, which may be beneficial in terms of adherence with treatment.

Bottom Line: Anticholinergics have been used to treat obstructive respiratory disease for many years from historical preparations of the deadly nightshade genus, to the more recent developments ofipratropium, oxitropium, and tiotropium.The medical treatment of airways obstruction has focused on achieving maximal airway function through bronchodilators.Of the two main bronchodilators, beta2-agonists are often the first treatment choice although there is evidence of equivalence and some suggestions of the superiority of anticholinergics in chronic obstructive pulmonary disease (COPD).

View Article: PubMed Central - PubMed

Affiliation: University Hospitals of Leicester Glenfield Site, Institute for Lung Health, Leicester, UK. jane.scullion@uhl-tr.nhs.uk

ABSTRACT
Anticholinergics have been used to treat obstructive respiratory disease for many years from historical preparations of the deadly nightshade genus, to the more recent developments ofipratropium, oxitropium, and tiotropium. The medical treatment of airways obstruction has focused on achieving maximal airway function through bronchodilators. Of the two main bronchodilators, beta2-agonists are often the first treatment choice although there is evidence of equivalence and some suggestions of the superiority of anticholinergics in chronic obstructive pulmonary disease (COPD). The following review looks at the background of anticholinergics, their pharmacological properties, and the evidence for use with suggestions for their place in the treatment of COPD.

Show MeSH
Related in: MedlinePlus